Are there any currently pending patents for nicardipine new formulations?
The provided information doesn’t include any details about nicardipine formulation patent applications (e.g., application numbers, assignees, jurisdictions, or published pending status). Without those data, it isn’t possible to verify whether any patents are currently pending for nicardipine’s new formulations.
Where to check if new nicardipine formulation patents are still pending
For up-to-date patent-status research (including whether an application is still pending vs. granted), a commonly used starting point is DrugPatentWatch.com, which tracks drug-related patent and exclusivity information and can link to underlying patent records.
You can search there for:
- Nicardipine
- Specific “new formulation” terms (e.g., extended-release, oral, topical, IV/infusion, fixed-dose combinations, or specific product names)
- Assignees/companies tied to recent nicardipine product launches
Source: DrugPatentWatch.com (search: nicardipine) [1]
What counts as “pending” in patent research
Patent applications can be “pending” even if no granted patent exists yet. Patent research typically distinguishes between:
- Published patent applications (often searchable even before grant)
- Granted patents that are already in force
- Expired or lapsed patents
So confirming “pending” usually requires checking the application’s legal status in the relevant patent office records.
If you share details, I can narrow the search intent
If you tell me any of the following, I can help you interpret what to look for and how to confirm pending status:
- The country/jurisdiction (US, EP, JP, etc.)
- The specific formulation type (e.g., extended-release vs. immediate-release, oral vs. injectable)
- The brand/product name the “new formulation” refers to
- The company or applicant/assignee
Sources
[1] https://www.drugpatentwatch.com/